Key Highlights

● AstraZeneca agreed to a $2 billion strategic Equity Investment in Summit, with a clinical collaboration on cancer studies.

● Stifel said there is no license and nothing sold but stock, so Summit keeps full ivonescimab Economics in its territories.

● The investment is through convertible preferred stock at $18.36 per common share, above Summit's recent average trading price.

● The stock closed at $17.96 on September 29, 2026, and sources differed on the size of the gain.

Summit Therapeutics Inc. (NASDAQ:SMMT) soared on Tuesday, September 29, 2026, after AstraZeneca agreed to make a $2 billion strategic equity investment in the company, paired with a clinical collaboration on cancer studies. The stock closed at $17.96. Sources differed on the size of the gain, with one showing a smaller rise at midday and others pointing to a much bigger jump.

Stifel's No License Verdict

Stifel analysts said there is no license and nothing else sold but stock, so Summit keeps full ivonescimab economics in its territories. That is an important distinction. When a big drugmaker partners with a smaller biotech, it often takes a license to the smaller company's drug, sharing in future sales and gaining control over development. Here AstraZeneca is buying shares instead, so Summit keeps the full commercial value of ivonescimab where it holds rights. BMO Capital Markets said the deal creates a meaningful strategic position without acquiring the company or licensing ivonescimab outright at this stage.

How the Deal Works

AstraZeneca is investing through convertible preferred stock priced at $18.36 per common share, above Summit's recent average trading price. Convertible Preferred Shares can later be exchanged for common stock, giving the investor a route to a meaningful ownership position. The companies will also collaborate on clinical studies in cancer. The investment was framed as clearing a financial overhang: late-stage cancer trials are expensive, and investors often worry a smaller biotech will need to sell shares at lower prices to fund them.

What Ivonescimab Is

Ivonescimab is a bispecific antibody, a single molecule designed to hit two targets at once. It blocks PD-1, a checkpoint that tumors use to hide from the immune system, and VEGF, a protein that helps tumors grow blood vessels. Combining both actions in one drug is one of the most closely watched ideas in oncology.

How the Tape Finished

Health care was mixed and the market slightly lower. The major indexes finished lower, with the S&P 500 down 12.85 points at 7,670.84 and the Dow Jones Industrial Average down 131.59 points at 51,349.92. The Nasdaq Composite ended nearly flat at 26,797.54. Long-term Treasury yields pressured stocks through the session, with the 30-year yield at its highest since 2002. The Conference Board's index of consumer confidence slid to 81.9, a 12-year low, from 88.6 the month before.

Fed Signals

Elsewhere in biotech, uniQure collapsed on disappointing Huntington's data while Iovance soared after raising its Revenue guidance. New York Fed President John Williams said there is no need for urgency after the central bank's September meeting, and odds of an October rate hike fell to roughly a coin flip. Other Fed officials, including Chicago Fed President Austan Goolsbee, sounded more hawkish.